A History of Recognition

An Illness Before It Had a Name

Long before researchers had a name for it, the condition we now call ME/CFS was leaving trails in the medical literature. Clusters of unexplained, debilitating illness appeared among staff at various institutions during the mid-twentieth century, bewildering the physicians who encountered them. The most consequential of these outbreaks unfolded in the summer of 1955 at the Royal Free Hospital in London, where more than two hundred members of staff — predominantly nurses — fell ill with profound fatigue, muscle pain, and neurological symptoms. The hospital was forced to close its wards for several months. When physicians Melvin Ramsay and colleagues documented the outbreak, they reached for a name that reflected what they were seeing: myalgic encephalomyelitis, or ME — a term acknowledging muscle pain, inflammation, and involvement of the brain and spinal cord.

That name mattered. It planted a flag: this was a disease of the body, with measurable, physiological features, not a peculiarity of the mind. Yet despite Ramsay's careful clinical descriptions, the medical mainstream was slow to follow. A 1970 reanalysis of the Royal Free outbreak suggested the episode might have been "mass hysteria" — a dismissal that would shadow patients for generations and prove extraordinarily difficult to dislodge.

The Epidemic That Forced a Conversation

For the next three decades, ME remained a medical curiosity: taken seriously by a small number of specialists, largely ignored by everyone else. Then, in the mid-1980s, something happened in a small Nevada resort town that was impossible to ignore. Beginning around 1984 and escalating through 1985, a cluster of patients near Incline Village on Lake Tahoe presented to local physicians Daniel Peterson and Paul Cheney with a constellation of crushing fatigue, cognitive difficulties, and physical incapacitation. Many had been active, healthy people before; now they could barely function. Peterson and Cheney alerted the Centers for Disease Control and Prevention (CDC), which investigated and ultimately found no infectious cause it could act on — a conclusion that frustrated patients and clinicians alike, but kept the illness in national conversation.

The Incline Village cluster galvanised advocacy and forced the CDC's hand. In 1988, the agency convened a working group and formally adopted the term chronic fatigue syndrome — CFS — publishing its first case definition in the Annals of Internal Medicine. It was a pivotal moment of institutional recognition, but it carried a cost: the new name emphasised a single symptom, fatigue, in a way that made the illness sound trivial. Patients, many of whom were profoundly disabled, found the term belittling. The tension between clinical convenience and patient dignity would not go away.

Criteria, Controversy, and Creeping Legitimacy

The 1988 CDC definition was a starting point, not an endpoint. It was revised substantially in 1994, when Keiji Fukuda and colleagues published what became known as the Fukuda criteria, again in the Annals of Internal Medicine. These criteria required six months of unexplained, debilitating fatigue alongside at least four of eight specified symptoms — including unrefreshing sleep, cognitive impairment, and post-exertional malaise, the hallmark worsening of symptoms after physical or mental effort. The Fukuda criteria became the dominant research standard internationally for roughly two decades, shaping which patients entered clinical trials and which did not.

Throughout the 1990s and 2000s, research was advancing slowly but meaningfully. Institutions including the National Institutes of Health in the United States began funding investigations into the biological underpinnings of the illness. Researchers examined immune dysfunction, autonomic nervous system abnormalities, and potential viral triggers including Epstein-Barr virus and Human herpesvirus 6. The European Network on ME/CFS, known as EUROMENE, would later work to harmonise research and clinical approaches across member countries. In Australia, Griffith University's National Centre for Neuroimmunology and Emerging Diseases — NCNED — led by researchers including Don Staines, became a significant hub for investigating the biological mechanisms of ME/CFS, particularly the role of calcium ion channels and neuroimmunological dysfunction. This was science insisting on a physiological reality that clinical medicine had been reluctant to fully accept.

Yet the same period also saw the entrenchment of a contested treatment model. Graded exercise therapy and cognitive behavioural therapy became widely recommended — the latter premised, in its ME/CFS application, on the idea that patients' beliefs about their illness were perpetuating their symptoms. Patient advocacy groups, including community networks and independent voices writing through platforms like Health Rising and Phoenix Rising, documented harm and pushed back vigorously. The argument was not merely semantic; it was about whether the illness was real in the way that cancer or multiple sclerosis is real.

A Turning Point: The 2015 Institute of Medicine Report

The clearest institutional vindication in ME/CFS history arrived in February 2015, when the United States Institute of Medicine — now the National Academy of Medicine — published a landmark report titled Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. The report, the product of a comprehensive review of the existing evidence, concluded unequivocally that ME/CFS is a serious, chronic, complex, systemic disease. It proposed new diagnostic criteria centring post-exertional malaise as a core, defining feature, and suggested the name systemic exertion intolerance disease (SEID) to reflect that exertion intolerance — not simply fatigue — was the illness's distinguishing characteristic.

The report carried weight precisely because of its source: an authoritative scientific body with no institutional stake in the psychosomatic model. It recommended that clinicians should be trained to recognise and take ME/CFS seriously, that research investment should increase dramatically, and that the stigma surrounding the illness was both unjustified and damaging. SEID as a name did not ultimately gain widespread clinical traction — ME/CFS remains the dominant term — but the report's conclusions reshaped the debate.

In the United Kingdom, a parallel reckoning unfolded through the National Institute for Health and Care Excellence. In 2021, NICE issued a substantially revised guideline on ME/CFS that made history by explicitly withdrawing its previous recommendations for graded exercise therapy and the form of CBT premised on perpetuating illness beliefs. The revised guideline acknowledged the evidence of patient harm and placed pacing — careful activity management within a patient's energy envelope — at the centre of its recommendations.

Long COVID and an Unexpected Accelerant

No external event has accelerated ME/CFS research as dramatically as the COVID-19 pandemic. As substantial numbers of people who recovered from acute COVID-19 began experiencing persistent symptoms — fatigue, cognitive difficulties, post-exertional malaise — that closely mirrored ME/CFS, researchers and clinicians who had spent careers studying ME/CFS found themselves at the centre of a suddenly urgent conversation. Long COVID drew unprecedented research funding, political attention, and public interest.

Crucially, it also lent new credibility to the physiological framework that ME/CFS patients and their advocates had been arguing for all along. The same post-exertional malaise, the same unrefreshing sleep, the same orthostatic intolerance — appearing now in patients whose illness onset was clearly documented and whose prior health was on record — made dismissal far harder to sustain. Organisations, including the National Institutes of Health, launched major research initiatives that encompassed both long COVID and ME/CFS. The illness that had waited decades at the margins of medicine was, suddenly and belatedly, a priority.

History rarely moves in straight lines, and the recognition of ME/CFS has certainly not. But the arc, traced from a closed London hospital ward in 1955 to the global research programmes of the 2020s, bends unmistakably toward acknowledgment.